
|Articles|April 26, 2023
AACU supports the PPI survey to update the MEI
Author(s)AACU
Advertisement
The American Medical Association is undertaking a 2023-2024 physician practice expense data collection effort with an independent research partner, Mathematica. The AACU is in favor of this effort in order provide an accurate update of the Medicare Economic Index and believes this survey is essential to the collection of practice cost information for use in our advocacy to support physicians. We have signed on to a letter that will be provided to each medical practice as part of the Mathematica invitation to participate in the survey effort.
The data will be shared with the Centers for Medicare & Medicaid Services in late 2024 to update the Medicare Economic Index and the Resource-Based Relative Value Scale.
Advertisement
Related to this article

enGene expects to initiate a BLA submission by the end of 2026.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5
